Aldeyra Therapeutics

ALDXPhase 3

Aldeyra Therapeutics is devoted to developing next-generation medicines for immune-mediated diseases through its innovative RASP modulator platform, which targets a family of pathogenic small molecules rather than single proteins. The company's most advanced candidate, reproxalap, has demonstrated rapid activity in multiple late-stage trials for dry eye disease, though it recently received a Complete Response Letter from the FDA. Aldeyra is also developing ADX-2191, an intraocular formulation of methotrexate with Orphan Drug Designation for rare retinal conditions, and ADX-629, an oral RASP modulator for systemic diseases, positioning it to address significant unmet needs across ophthalmology and immunology.

Market Cap

$108.9M

Focus

Small Molecules

ALDX · Stock Price

USD 1.813.04 (-62.68%)

Historical price data

AI Company Overview

Technology Platform

The Reactive Aldehyde Species (RASP) modulator platform targets pathogenic small molecules that drive inflammation, aiming to downregulate multiple pro-inflammatory pathways simultaneously rather than inhibiting a single protein target.

Pipeline Snapshot

35 drugs in pipeline, 14 in Phase 3

Drug	Indication	Stage
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic Solution	Allergic Conjunctivitis	Phase 3
ICM ADX-2191 injection + Monthly ADX-2191 injection	Primary Vitreoretinal Lymphoma	Phase 3
Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) +...	Allergic Conjunctivitis	Phase 3
ADX-2191 (intravitreal methotrexate 0.8%)	Proliferative Vitreoretinopathy	Phase 3
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic Solution	Dry Eye Disease	Phase 3

Funding History

Total raised: $140M

PIPE$60MUndisclosedSep 15, 2020

IPO$40MUndisclosedJul 24, 2014

Series B$25MFidelity BiosciencesJun 15, 2014

Series A$15MFidelity BiosciencesJun 15, 2012

Opportunities

Approval of reproxalap would open the large dry eye and allergic conjunctivitis markets and validate the RASP platform for broader applications.

ADX-2191 addresses severe unmet needs in rare retinal diseases with no approved therapies, offering a high-value orphan drug pathway.

The oral ADX-629 candidate could expand the company's reach into massive systemic disease markets like autoimmune disorders and metabolic disease.

Risk Factors

The company faces significant regulatory risk following the Complete Response Letter for reproxalap, with potential for further delays or non-approval.

Its novel RASP mechanism is unproven, and clinical trials for any pipeline asset may fail.

As a pre-revenue company, it is dependent on raising capital, which can be challenging and dilutive, especially after clinical or regulatory setbacks.

Competitive Landscape

In dry eye disease, reproxalap competes with established brands like Restasis, Xiidra, and Tyrvaya, differentiating on its novel mechanism and rapid onset of action. For its rare disease program ADX-2191, the main competition is the unsafe, unstandardized practice of pharmacy compounding, against which it offers a regulated, sterile formulation. At the platform level, Aldeyra appears to have a first-mover advantage with no other known companies developing RASP-targeted therapies.